导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -12.62% | 3958/4773 |
| 近一周 | -2.53% | 4001/5465 |
| 近一月 | -2.78% | 1898/5421 |
| 近一季 | -2.60% | 1442/5231 |
| 近半年 | -4.65% | 2897/4920 |
| 近一年 | -15.97% | 3791/4394 |
| 近两年 | 27.11% | 2407/2954 |
| 近三年 | 7.79% | 1801/2253 |
| 成立以来 | 12.37% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-14.46% 4657/4961 |
8.47% 2590/5312 |
- - |
- - |
| 2025 | 3.16% 3144/4813 |
-6.73% 3391/3635 |
4.11% 859/4076 |
10.60% 3269/4524 |
-3.95% 3363/4813 |
| 2024 | 26.26% 229/3463 |
-4.75% 1757/2808 |
-8.30% 2208/3014 |
42.49% 50/3129 |
1.45% 1068/3463 |
| 2023 | 3.54% 274/2656 |
3.91% 1096/2280 |
-2.83% 682/2385 |
7.23% 55/2515 |
-4.38% 993/2655 |
| 2022 | -25.04% 1285/2207 |
-17.84% 1271/1919 |
2.00% 1387/2016 |
-15.49% 1303/2113 |
5.85% 426/2208 |
| 2021 | -4.86% 963/1822 |
-14.65% 1180/1255 |
6.79% 718/1330 |
2.83% 427/1466 |
1.50% 899/1822 |
| 2020 | 19.78% 728/1250 |
-9.73% 715/1028 |
9.55% 790/1067 |
19.89% 65/1164 |
1.03% 1044/1184 |
| 2019 | 46.43% 136/1092 |
46.53% 17/754 |
-5.71% 480/804 |
-3.99% 753/850 |
10.39% 142/918 |
| 2018 | -26.81% 402/834 |
- - |
- - |
- - |
-1.34% 11/691 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 汇添富中证全指证券公司ETF联接(LOF)C VS. 长安沪深300非周期A(740101) |